A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
Summary
The purpose of this study is to determine the efficacy and safety of the study drug ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis.
Timeline
- Start
- 2018-04-26
- Primary completion
- 2020-06-04
- Completion
- 2020-06-04
Outcome
Met primary endpoint
registry analysis (superiority test); Placebo vs Ixekizumab 80mg Q4W; p <0.0001; Odds Ratio (OR) 99.99 (95% CI 33.57 to 99.99); Regression, Logistic NCT03364309 ↗
registry analysis (superiority test); Placebo vs Ixekizumab 80mg Q2W; p <0.001; Odds Ratio (OR) 99.99 (95% CI 52.49 to 99.99); Regression, Logistic NCT03364309 ↗
registry analysis (superiority test); Placebo vs Ixekizumab 80mg Q4W; p <0.001; Odds Ratio (OR) 79.95 (95% CI 32.76 to 99.99); Regression, Logistic NCT03364309 ↗
registry analysis (superiority test); Placebo vs Ixekizumab 80mg Q2W; p <0.001; Odds Ratio (OR) 99.99 (95% CI 64.87 to 99.99); Regression, Logistic NCT03364309 ↗
Publications
- Gao X, Pan W, Zheng M, Li F, Dong X, Lv D, Guo Z, Li J, Wang X, Geng S. Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab. Adv Ther. 2025 Jan;42(1):334-347. doi: 10.1007/s12325-024-03030-5. Epub 2024 Nov 13.
- Li X, Ding Y, Zhang C, Lu Y, Li F, Pan W, Guo S, Li J, Zhao B, Zheng J. Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study. Adv Ther. 2025 Jan;42(1):146-163. doi: 10.1007/s12325-024-02976-w. Epub 2024 Sep 30.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixekizumab | Monoclonal antibody | 80 mg | Subcutaneous |